By LabPulse.com staff writers

August 19, 2019 -- NeuroFlow and Genomind are partnering on mental health services that incorporate pharmacogenomic testing to help guide treatment for a range of conditions, including anxiety, depression, post-traumatic stress disorder, and obsessive-compulsive disorder.

Philadelphia-based NeuroFlow markets a mobile app for smartphones that helps patients with mental health conditions track their wellness through journaling about their activities and fluctuations in mood. King of Prussia, PA-based Genomind markets the Genomind Professional PGx Express cheek swab test, which profiles the genetics of patients and helps clinicians make decisions about what medications to prescribe for mental health conditions.

The companies said that physicians using NeuroFlow's platform will now offer Genomind testing and results reporting on pharmacogenomic factors related to mental health and response to medications.

Myriad's GeneSight woes reflect closer FDA oversight
Myriad Genetics stock took a hit with an earnings report that disappointed Wall Street and the disclosure that the company has been asked by the U.S....
Myriad Genetics depression test hits Kroger pharmacies
Myriad Genetics' GeneSight pharmacogenomics test for depression is being introduced in hundreds of Kroger Health U.S. pharmacies, as part of a personalized...
Failed study leaves CRP test hanging as biomarker in bipolar depression
Investigators tried and failed to use C-reactive protein (CRP) as an inflammatory biomarker for picking patients with bipolar depression for drug treatment...

Copyright © 2019 LabPulse.com

Last Updated np 8/19/2019 1:12:00 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email